Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalen
A phase 1/2 trial of Pembrolizumab, Pemetrexed, Gemcitabine in non-small-cell lung cancer and small-cell lung cancer, run by Inhibrx Biosciences, Inc, now recruiting.
Overview
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) is a phase 1/2 interventional study registered as NCT04198766 by Inhibrx Biosciences, Inc, with 340 participants planned, started 2019-12-10 and due to reach its primary completion in 2033-07. Interventions recorded: INBRX-106 - Hexavalent OX40 agonist antibody, pembrolizumab 200 mg, pembrolizumab 400 mg, Carboplatin AUC-5, Carboplatin AUC-6. Conditions listed: Solid Tumor, Non-Small Cell Lung Cancer, Head and Neck Cancer, Melanoma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) Over Intravenous Pembrol
Shares Renal cell carcinoma, Melanoma, Pembrolizumab, Small-cell lung cancer.
- TrialPhase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
Shares Renal cell carcinoma, Melanoma, Pembrolizumab, Small-cell lung cancer.
- TrialSafety, Immunogenicity and Preliminary Clinical Activity Study of PDC*lung01 Cancer Vaccine in NSCLC
Shares Pemetrexed, Pembrolizumab, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Study of NDI 1150-101 in Patients With Solid Tumors
Shares Renal cell carcinoma, Pembrolizumab, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Sm
Shares Pemetrexed, Gemcitabine, Pembrolizumab, Small-cell lung cancer.
- TrialA Beta-only IL-2 ImmunoTherapY Study
Shares Renal cell carcinoma, Pembrolizumab, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialStudy of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
Shares Pemetrexed, Pembrolizumab, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in Combination With Pembrolizumab as First-Line Treatment for PD-L1 Negative P
Shares Pemetrexed, Pembrolizumab, Small-cell lung cancer, Non-small-cell lung cancer.